Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 98 | 2023 | 1426 | 12.620 |
Why?
|
Diabetes Mellitus, Type 2 | 30 | 2023 | 592 | 8.830 |
Why?
|
Diet | 51 | 2023 | 747 | 8.460 |
Why?
|
Mammography | 53 | 2022 | 176 | 8.010 |
Why?
|
Breast | 31 | 2019 | 134 | 7.310 |
Why?
|
Soy Foods | 22 | 2016 | 59 | 6.630 |
Why?
|
Premenopause | 38 | 2021 | 103 | 6.590 |
Why?
|
Isoflavones | 27 | 2021 | 125 | 5.210 |
Why?
|
Adiposity | 16 | 2022 | 145 | 5.120 |
Why?
|
Middle Aged | 153 | 2023 | 9642 | 4.360 |
Why?
|
Aged | 115 | 2023 | 6448 | 4.270 |
Why?
|
Cohort Studies | 61 | 2023 | 1422 | 4.250 |
Why?
|
Risk Factors | 96 | 2023 | 3414 | 4.190 |
Why?
|
Female | 208 | 2023 | 19873 | 4.160 |
Why?
|
Obesity | 22 | 2023 | 965 | 3.620 |
Why?
|
Mammary Glands, Human | 9 | 2018 | 39 | 3.460 |
Why?
|
Hawaii | 74 | 2021 | 1878 | 3.450 |
Why?
|
Humans | 221 | 2023 | 34853 | 3.340 |
Why?
|
Estrogens | 11 | 2016 | 190 | 3.260 |
Why?
|
Body Mass Index | 45 | 2023 | 775 | 3.180 |
Why?
|
Intra-Abdominal Fat | 7 | 2022 | 39 | 2.770 |
Why?
|
Feeding Behavior | 15 | 2018 | 418 | 2.620 |
Why?
|
Lymphoma, Non-Hodgkin | 10 | 2015 | 37 | 2.520 |
Why?
|
Incidence | 31 | 2023 | 882 | 2.430 |
Why?
|
Overweight | 8 | 2023 | 233 | 2.400 |
Why?
|
Absorptiometry, Photon | 13 | 2023 | 73 | 2.310 |
Why?
|
Case-Control Studies | 36 | 2020 | 1056 | 2.210 |
Why?
|
Nipple Aspirate Fluid | 5 | 2013 | 14 | 2.140 |
Why?
|
Adult | 95 | 2023 | 11034 | 2.130 |
Why?
|
Proportional Hazards Models | 29 | 2022 | 423 | 2.030 |
Why?
|
Prospective Studies | 33 | 2023 | 1353 | 1.870 |
Why?
|
Male | 81 | 2023 | 18870 | 1.820 |
Why?
|
Diet, Mediterranean | 5 | 2020 | 35 | 1.800 |
Why?
|
Inflammation | 8 | 2022 | 577 | 1.750 |
Why?
|
Colorectal Neoplasms | 8 | 2022 | 413 | 1.700 |
Why?
|
Postmenopause | 17 | 2020 | 125 | 1.690 |
Why?
|
Japan | 20 | 2019 | 296 | 1.540 |
Why?
|
Health Behavior | 7 | 2015 | 491 | 1.410 |
Why?
|
C-Reactive Protein | 10 | 2022 | 147 | 1.400 |
Why?
|
Insulin-Like Growth Factor I | 7 | 2016 | 66 | 1.350 |
Why?
|
California | 15 | 2019 | 436 | 1.350 |
Why?
|
Leptin | 9 | 2018 | 115 | 1.310 |
Why?
|
Soybean Proteins | 5 | 2014 | 38 | 1.280 |
Why?
|
Sleep | 2 | 2019 | 122 | 1.200 |
Why?
|
Magnetic Resonance Imaging | 6 | 2022 | 468 | 1.150 |
Why?
|
Follow-Up Studies | 19 | 2022 | 964 | 1.150 |
Why?
|
Cross-Sectional Studies | 29 | 2023 | 2561 | 1.120 |
Why?
|
Adiponectin | 6 | 2017 | 52 | 1.110 |
Why?
|
Nutrition Assessment | 5 | 2018 | 77 | 1.070 |
Why?
|
Body Fat Distribution | 3 | 2021 | 23 | 1.060 |
Why?
|
Cross-Over Studies | 11 | 2021 | 102 | 1.040 |
Why?
|
Cacao | 2 | 2018 | 10 | 1.010 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 6 | 2010 | 22 | 0.990 |
Why?
|
Survivors | 4 | 2015 | 126 | 0.980 |
Why?
|
Parity | 4 | 2015 | 46 | 0.980 |
Why?
|
Meat | 5 | 2013 | 41 | 0.960 |
Why?
|
Body Composition | 6 | 2023 | 146 | 0.930 |
Why?
|
Micronutrients | 3 | 2019 | 42 | 0.910 |
Why?
|
Body Weight | 5 | 2015 | 404 | 0.910 |
Why?
|
Feces | 3 | 2021 | 110 | 0.910 |
Why?
|
Smoking | 13 | 2019 | 903 | 0.900 |
Why?
|
Neoplasms | 10 | 2015 | 1033 | 0.880 |
Why?
|
Nipples | 3 | 2013 | 14 | 0.850 |
Why?
|
Dietary Fiber | 3 | 2020 | 42 | 0.840 |
Why?
|
Tocopherols | 3 | 2021 | 62 | 0.840 |
Why?
|
Diabetes Mellitus | 7 | 2019 | 465 | 0.830 |
Why?
|
Aged, 80 and over | 17 | 2022 | 2333 | 0.820 |
Why?
|
Alcohol Drinking | 5 | 2015 | 490 | 0.810 |
Why?
|
Gonadal Steroid Hormones | 3 | 2006 | 50 | 0.790 |
Why?
|
Chronic Disease | 2 | 2019 | 469 | 0.790 |
Why?
|
Adolescent | 23 | 2023 | 5035 | 0.780 |
Why?
|
Logistic Models | 12 | 2017 | 894 | 0.780 |
Why?
|
Mortality | 2 | 2016 | 150 | 0.760 |
Why?
|
United States | 15 | 2023 | 3894 | 0.760 |
Why?
|
Flavonoids | 2 | 2018 | 78 | 0.730 |
Why?
|
Phytoestrogens | 4 | 2013 | 35 | 0.720 |
Why?
|
Lipids | 3 | 2018 | 222 | 0.710 |
Why?
|
Nutritional Physiological Phenomena | 3 | 2011 | 35 | 0.700 |
Why?
|
Hydroxyestrones | 4 | 2017 | 8 | 0.690 |
Why?
|
Thinness | 1 | 2019 | 29 | 0.690 |
Why?
|
Coffee | 2 | 2023 | 20 | 0.680 |
Why?
|
Life Style | 7 | 2017 | 288 | 0.680 |
Why?
|
Risk Assessment | 11 | 2020 | 727 | 0.680 |
Why?
|
Vimentin | 1 | 2018 | 32 | 0.680 |
Why?
|
Estrone | 4 | 2013 | 21 | 0.670 |
Why?
|
Anticarcinogenic Agents | 2 | 2009 | 65 | 0.660 |
Why?
|
Puberty | 2 | 2011 | 25 | 0.660 |
Why?
|
Receptors, Progesterone | 4 | 2019 | 78 | 0.650 |
Why?
|
Patient Compliance | 6 | 2012 | 202 | 0.640 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2018 | 89 | 0.640 |
Why?
|
Los Angeles | 13 | 2021 | 368 | 0.640 |
Why?
|
Estradiol | 5 | 2013 | 244 | 0.640 |
Why?
|
Oxidative Stress | 2 | 2015 | 874 | 0.640 |
Why?
|
Meat Products | 1 | 2017 | 6 | 0.620 |
Why?
|
Inflammation Mediators | 1 | 2018 | 120 | 0.620 |
Why?
|
Receptors, Estrogen | 3 | 2019 | 145 | 0.610 |
Why?
|
Time Factors | 9 | 2019 | 1681 | 0.600 |
Why?
|
Chromatography, Liquid | 3 | 2014 | 140 | 0.590 |
Why?
|
Carotenoids | 5 | 2021 | 70 | 0.590 |
Why?
|
Pilot Projects | 10 | 2019 | 628 | 0.580 |
Why?
|
Gene Expression | 2 | 2018 | 639 | 0.570 |
Why?
|
Sepsis | 1 | 2017 | 76 | 0.570 |
Why?
|
Age Factors | 11 | 2015 | 1007 | 0.560 |
Why?
|
Odds Ratio | 9 | 2019 | 517 | 0.540 |
Why?
|
gamma-Tocopherol | 4 | 2019 | 18 | 0.530 |
Why?
|
Antioxidants | 4 | 2015 | 386 | 0.530 |
Why?
|
Reproducibility of Results | 8 | 2018 | 901 | 0.520 |
Why?
|
Prognosis | 11 | 2019 | 707 | 0.510 |
Why?
|
Liver | 1 | 2017 | 447 | 0.510 |
Why?
|
Plant Preparations | 2 | 2013 | 21 | 0.510 |
Why?
|
Stroke | 1 | 2018 | 274 | 0.500 |
Why?
|
Medicare | 4 | 2023 | 188 | 0.490 |
Why?
|
Health Status Disparities | 3 | 2015 | 583 | 0.490 |
Why?
|
Adipokines | 1 | 2014 | 24 | 0.490 |
Why?
|
Survival Rate | 7 | 2018 | 310 | 0.480 |
Why?
|
Phenotype | 7 | 2022 | 650 | 0.480 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2011 | 9 | 0.470 |
Why?
|
Survival Analysis | 5 | 2020 | 322 | 0.470 |
Why?
|
Epithelial Cells | 2 | 2013 | 366 | 0.470 |
Why?
|
Mass Spectrometry | 2 | 2012 | 255 | 0.460 |
Why?
|
Coffea | 1 | 2013 | 3 | 0.460 |
Why?
|
Menstrual Cycle | 2 | 2004 | 34 | 0.460 |
Why?
|
Tissue Array Analysis | 2 | 2013 | 65 | 0.460 |
Why?
|
Attitude to Health | 3 | 2005 | 311 | 0.450 |
Why?
|
Population Groups | 2 | 2022 | 56 | 0.450 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2009 | 112 | 0.450 |
Why?
|
Erythrocyte Membrane | 1 | 2012 | 20 | 0.440 |
Why?
|
Vitamin D | 6 | 2023 | 176 | 0.440 |
Why?
|
Phytotherapy | 1 | 2012 | 62 | 0.430 |
Why?
|
Isoprostanes | 1 | 2012 | 14 | 0.430 |
Why?
|
Oncology Service, Hospital | 1 | 2012 | 1 | 0.430 |
Why?
|
Child | 12 | 2023 | 2875 | 0.430 |
Why?
|
Women's Health | 2 | 2011 | 135 | 0.430 |
Why?
|
Polymorphism, Single Nucleotide | 9 | 2022 | 638 | 0.420 |
Why?
|
Reproductive History | 1 | 2012 | 18 | 0.420 |
Why?
|
Prostatic Neoplasms | 3 | 2022 | 794 | 0.420 |
Why?
|
RNA, Ribosomal, 16S | 4 | 2022 | 165 | 0.420 |
Why?
|
Fatty Acids | 1 | 2012 | 118 | 0.410 |
Why?
|
Eating | 4 | 2022 | 152 | 0.410 |
Why?
|
Cytochrome P-450 CYP1A2 | 3 | 2007 | 21 | 0.400 |
Why?
|
Steroids | 1 | 2011 | 43 | 0.400 |
Why?
|
Blood Glucose | 2 | 2010 | 333 | 0.400 |
Why?
|
Vitamin D Deficiency | 4 | 2023 | 94 | 0.400 |
Why?
|
Complementary Therapies | 6 | 2012 | 45 | 0.390 |
Why?
|
Genetic Predisposition to Disease | 8 | 2022 | 528 | 0.380 |
Why?
|
SEER Program | 6 | 2019 | 87 | 0.380 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 6 | 2012 | 445 | 0.380 |
Why?
|
Neoplasm Staging | 7 | 2011 | 269 | 0.380 |
Why?
|
Prevalence | 8 | 2012 | 1425 | 0.380 |
Why?
|
Motor Activity | 3 | 2015 | 393 | 0.380 |
Why?
|
Internship and Residency | 1 | 2012 | 121 | 0.380 |
Why?
|
Linear Models | 6 | 2021 | 253 | 0.380 |
Why?
|
Longitudinal Studies | 6 | 2019 | 841 | 0.370 |
Why?
|
Anthropometry | 4 | 2021 | 91 | 0.370 |
Why?
|
Confidence Intervals | 5 | 2013 | 151 | 0.370 |
Why?
|
Plant Extracts | 1 | 2012 | 250 | 0.360 |
Why?
|
Weight Gain | 1 | 2010 | 128 | 0.360 |
Why?
|
Menopause | 3 | 2007 | 54 | 0.360 |
Why?
|
Immunohistochemistry | 4 | 2018 | 859 | 0.360 |
Why?
|
Predictive Value of Tests | 5 | 2018 | 424 | 0.350 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 1 | 2009 | 6 | 0.350 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2009 | 20 | 0.350 |
Why?
|
Magnesium | 1 | 2009 | 95 | 0.350 |
Why?
|
Catechol O-Methyltransferase | 2 | 2007 | 11 | 0.330 |
Why?
|
Regression Analysis | 7 | 2015 | 429 | 0.330 |
Why?
|
Risk | 5 | 2014 | 256 | 0.330 |
Why?
|
Lymphoma, Follicular | 1 | 2008 | 2 | 0.330 |
Why?
|
Hormones | 2 | 2013 | 51 | 0.320 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 19 | 0.320 |
Why?
|
Lymphoma, T-Cell | 1 | 2008 | 25 | 0.320 |
Why?
|
Lymphoma, B-Cell | 1 | 2008 | 22 | 0.320 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 18 | 0.320 |
Why?
|
Comorbidity | 4 | 2018 | 606 | 0.320 |
Why?
|
Sex Factors | 8 | 2013 | 859 | 0.320 |
Why?
|
Prolactin | 1 | 2007 | 59 | 0.310 |
Why?
|
Adipose Tissue | 5 | 2021 | 167 | 0.310 |
Why?
|
Fruit | 5 | 2021 | 159 | 0.310 |
Why?
|
Norway | 7 | 2016 | 9 | 0.300 |
Why?
|
Diet Surveys | 6 | 2009 | 96 | 0.300 |
Why?
|
Vegetables | 4 | 2021 | 135 | 0.290 |
Why?
|
Progesterone | 4 | 2012 | 117 | 0.290 |
Why?
|
Health Status Indicators | 1 | 2007 | 73 | 0.290 |
Why?
|
Interleukin-6 | 3 | 2014 | 140 | 0.290 |
Why?
|
Radiographic Image Enhancement | 1 | 2006 | 10 | 0.290 |
Why?
|
China | 4 | 2012 | 178 | 0.280 |
Why?
|
Obesity, Abdominal | 2 | 2019 | 26 | 0.280 |
Why?
|
Population Surveillance | 5 | 2012 | 231 | 0.280 |
Why?
|
Exercise | 3 | 2017 | 524 | 0.280 |
Why?
|
Young Adult | 8 | 2016 | 4012 | 0.270 |
Why?
|
Heptachlor | 1 | 2005 | 2 | 0.260 |
Why?
|
Cause of Death | 2 | 2018 | 154 | 0.260 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2010 | 233 | 0.260 |
Why?
|
Cholesterol, HDL | 2 | 2017 | 87 | 0.260 |
Why?
|
Triglycerides | 2 | 2017 | 129 | 0.260 |
Why?
|
Insecticides | 1 | 2005 | 47 | 0.250 |
Why?
|
Food Contamination | 1 | 2005 | 55 | 0.250 |
Why?
|
Family Health | 2 | 2017 | 47 | 0.250 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2018 | 325 | 0.240 |
Why?
|
Sarcopenia | 1 | 2023 | 9 | 0.240 |
Why?
|
Iceland | 2 | 2022 | 5 | 0.240 |
Why?
|
Emigration and Immigration | 1 | 2004 | 72 | 0.240 |
Why?
|
Malnutrition | 1 | 2023 | 45 | 0.230 |
Why?
|
Registries | 6 | 2019 | 330 | 0.220 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2023 | 63 | 0.220 |
Why?
|
Sex Distribution | 3 | 2011 | 212 | 0.220 |
Why?
|
Subcutaneous Fat | 1 | 2022 | 12 | 0.220 |
Why?
|
Mastectomy, Segmental | 1 | 2002 | 18 | 0.210 |
Why?
|
Insurance Claim Review | 1 | 2002 | 24 | 0.210 |
Why?
|
Cell Count | 2 | 2012 | 129 | 0.210 |
Why?
|
Chromatography, High Pressure Liquid | 3 | 2013 | 406 | 0.210 |
Why?
|
Whole Body Imaging | 1 | 2021 | 25 | 0.210 |
Why?
|
Body Height | 1 | 2022 | 52 | 0.210 |
Why?
|
Health Surveys | 4 | 2012 | 358 | 0.200 |
Why?
|
Vitamin A | 1 | 2021 | 87 | 0.200 |
Why?
|
Retrospective Studies | 5 | 2023 | 1961 | 0.190 |
Why?
|
Databases, Factual | 1 | 2002 | 288 | 0.190 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2018 | 164 | 0.190 |
Why?
|
Genistein | 2 | 2013 | 41 | 0.190 |
Why?
|
Pregnancy | 3 | 2022 | 1503 | 0.190 |
Why?
|
Tamoxifen | 2 | 2018 | 61 | 0.190 |
Why?
|
Metformin | 1 | 2021 | 64 | 0.190 |
Why?
|
Prediabetic State | 1 | 2021 | 51 | 0.190 |
Why?
|
DNA-Binding Proteins | 2 | 2015 | 522 | 0.190 |
Why?
|
Nutrition Surveys | 2 | 2014 | 228 | 0.180 |
Why?
|
Glucose | 1 | 2021 | 217 | 0.180 |
Why?
|
Calcifediol | 2 | 2023 | 14 | 0.180 |
Why?
|
Diet, Reducing | 1 | 2019 | 22 | 0.180 |
Why?
|
Genome-Wide Association Study | 5 | 2022 | 271 | 0.180 |
Why?
|
Multifactorial Inheritance | 1 | 2019 | 14 | 0.180 |
Why?
|
Caloric Restriction | 1 | 2019 | 29 | 0.170 |
Why?
|
Double-Blind Method | 3 | 2017 | 269 | 0.170 |
Why?
|
Aging | 2 | 2017 | 639 | 0.170 |
Why?
|
Arizona | 3 | 2007 | 92 | 0.170 |
Why?
|
Sex Hormone-Binding Globulin | 3 | 2017 | 18 | 0.170 |
Why?
|
Flavanones | 1 | 2018 | 7 | 0.170 |
Why?
|
Radiation, Ionizing | 1 | 2018 | 13 | 0.160 |
Why?
|
Sensitivity and Specificity | 3 | 2011 | 555 | 0.160 |
Why?
|
Bacteria | 1 | 2021 | 245 | 0.160 |
Why?
|
Testosterone | 2 | 2012 | 181 | 0.160 |
Why?
|
Perimenopause | 1 | 2017 | 4 | 0.160 |
Why?
|
France | 1 | 2017 | 17 | 0.160 |
Why?
|
Feasibility Studies | 2 | 2008 | 196 | 0.150 |
Why?
|
Estrogen Receptor alpha | 2 | 2016 | 105 | 0.150 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 106 | 0.150 |
Why?
|
Dyslipidemias | 1 | 2017 | 42 | 0.150 |
Why?
|
Singapore | 2 | 2010 | 72 | 0.150 |
Why?
|
Energy Intake | 2 | 2015 | 160 | 0.150 |
Why?
|
Body Image | 1 | 2017 | 68 | 0.150 |
Why?
|
Circadian Rhythm | 1 | 2019 | 212 | 0.150 |
Why?
|
Soy Milk | 2 | 2008 | 6 | 0.150 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2016 | 18 | 0.140 |
Why?
|
Indoles | 1 | 2017 | 154 | 0.140 |
Why?
|
Diet Records | 2 | 2014 | 56 | 0.140 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2015 | 4 | 0.140 |
Why?
|
Canada | 1 | 2016 | 121 | 0.140 |
Why?
|
F2-Isoprostanes | 1 | 2015 | 20 | 0.140 |
Why?
|
Creatinine | 2 | 2014 | 101 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 178 | 0.130 |
Why?
|
Insulin Resistance | 1 | 2017 | 177 | 0.130 |
Why?
|
Enhancer Elements, Genetic | 1 | 2015 | 60 | 0.130 |
Why?
|
Polymorphism, Genetic | 2 | 2007 | 165 | 0.130 |
Why?
|
Kallikreins | 1 | 2014 | 10 | 0.120 |
Why?
|
Food | 1 | 2015 | 95 | 0.120 |
Why?
|
alpha-Tocopherol | 1 | 2014 | 25 | 0.120 |
Why?
|
Ubiquinone | 1 | 2014 | 21 | 0.120 |
Why?
|
Trans-Activators | 1 | 2015 | 167 | 0.120 |
Why?
|
Luteal Phase | 1 | 2013 | 5 | 0.120 |
Why?
|
Carrier Proteins | 1 | 2016 | 287 | 0.120 |
Why?
|
Area Under Curve | 1 | 2014 | 91 | 0.120 |
Why?
|
Cell Cycle Proteins | 1 | 2016 | 220 | 0.120 |
Why?
|
Cross-Cultural Comparison | 2 | 2004 | 100 | 0.120 |
Why?
|
Educational Status | 3 | 2015 | 295 | 0.120 |
Why?
|
Hormone Replacement Therapy | 3 | 2015 | 41 | 0.120 |
Why?
|
Colonoscopy | 1 | 2014 | 98 | 0.120 |
Why?
|
Neoplasm Invasiveness | 3 | 2014 | 247 | 0.120 |
Why?
|
Adolescent Behavior | 2 | 2007 | 243 | 0.120 |
Why?
|
Parturition | 1 | 2013 | 22 | 0.120 |
Why?
|
Prostate-Specific Antigen | 1 | 2014 | 95 | 0.120 |
Why?
|
Ovarian Neoplasms | 1 | 2016 | 303 | 0.110 |
Why?
|
Infant | 2 | 2008 | 1014 | 0.110 |
Why?
|
Caffeine | 1 | 2013 | 26 | 0.110 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 628 | 0.110 |
Why?
|
Matrix Metalloproteinases | 1 | 2012 | 44 | 0.110 |
Why?
|
Minnesota | 1 | 2012 | 39 | 0.110 |
Why?
|
Causality | 1 | 2012 | 45 | 0.110 |
Why?
|
Child, Preschool | 2 | 2008 | 1318 | 0.110 |
Why?
|
Waist-Hip Ratio | 1 | 2012 | 32 | 0.110 |
Why?
|
Proliferating Cell Nuclear Antigen | 2 | 2009 | 42 | 0.110 |
Why?
|
Korea | 1 | 2012 | 43 | 0.110 |
Why?
|
Mass Screening | 2 | 2014 | 427 | 0.110 |
Why?
|
Mexican Americans | 1 | 2014 | 177 | 0.110 |
Why?
|
Dietary Supplements | 2 | 2005 | 196 | 0.110 |
Why?
|
Microfilament Proteins | 1 | 2012 | 64 | 0.110 |
Why?
|
Philippines | 1 | 2012 | 72 | 0.110 |
Why?
|
Waist Circumference | 1 | 2012 | 82 | 0.100 |
Why?
|
Physician-Patient Relations | 2 | 2003 | 118 | 0.100 |
Why?
|
Food Analysis | 1 | 2011 | 30 | 0.100 |
Why?
|
Cell Cycle | 1 | 2013 | 309 | 0.100 |
Why?
|
Radioimmunoassay | 1 | 2011 | 66 | 0.100 |
Why?
|
Urologic Neoplasms | 1 | 2011 | 3 | 0.100 |
Why?
|
Limit of Detection | 1 | 2011 | 56 | 0.100 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2011 | 15 | 0.100 |
Why?
|
Socioeconomic Factors | 4 | 2015 | 1003 | 0.100 |
Why?
|
Treatment Outcome | 3 | 2022 | 1349 | 0.100 |
Why?
|
Cholesterol | 1 | 2012 | 194 | 0.100 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2011 | 32 | 0.100 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2010 | 4 | 0.100 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 4 | 0.100 |
Why?
|
Disease-Free Survival | 1 | 2011 | 114 | 0.100 |
Why?
|
Ethanol | 1 | 2012 | 188 | 0.090 |
Why?
|
Transcription Factors | 1 | 2015 | 653 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 2 | 2012 | 375 | 0.090 |
Why?
|
Hypertension | 1 | 2017 | 770 | 0.090 |
Why?
|
Cell Proliferation | 2 | 2013 | 1149 | 0.090 |
Why?
|
Oxidation-Reduction | 1 | 2011 | 407 | 0.090 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 968 | 0.090 |
Why?
|
Epidemiologic Studies | 1 | 2010 | 31 | 0.090 |
Why?
|
Multivariate Analysis | 2 | 2008 | 570 | 0.090 |
Why?
|
Chi-Square Distribution | 2 | 2011 | 213 | 0.090 |
Why?
|
Immune System Diseases | 1 | 2009 | 20 | 0.090 |
Why?
|
Tandem Mass Spectrometry | 1 | 2011 | 173 | 0.090 |
Why?
|
Placebos | 1 | 2009 | 38 | 0.090 |
Why?
|
Mothers | 1 | 2011 | 164 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 984 | 0.090 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2009 | 21 | 0.090 |
Why?
|
Chemokine CCL4 | 1 | 2008 | 18 | 0.090 |
Why?
|
Cytokines | 1 | 2013 | 569 | 0.090 |
Why?
|
Quality of Life | 4 | 2012 | 459 | 0.090 |
Why?
|
Parathyroid Hormone | 1 | 2009 | 36 | 0.090 |
Why?
|
Ki-67 Antigen | 1 | 2009 | 32 | 0.090 |
Why?
|
Genotype | 4 | 2015 | 641 | 0.090 |
Why?
|
Hysterectomy | 1 | 2008 | 29 | 0.080 |
Why?
|
Bone Density | 1 | 2009 | 76 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2016 | 781 | 0.080 |
Why?
|
Patient Satisfaction | 3 | 2005 | 141 | 0.080 |
Why?
|
Fermentation | 1 | 2008 | 25 | 0.080 |
Why?
|
Urinalysis | 2 | 2005 | 31 | 0.080 |
Why?
|
Research Design | 2 | 2007 | 292 | 0.080 |
Why?
|
Genetic Variation | 1 | 2010 | 328 | 0.080 |
Why?
|
Dairy Products | 2 | 2005 | 33 | 0.080 |
Why?
|
Asia | 2 | 2006 | 74 | 0.080 |
Why?
|
Sex Characteristics | 1 | 2009 | 213 | 0.080 |
Why?
|
Social Class | 1 | 2009 | 228 | 0.080 |
Why?
|
Chemokine CCL2 | 1 | 2008 | 82 | 0.080 |
Why?
|
Specimen Handling | 1 | 2008 | 49 | 0.080 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2007 | 21 | 0.080 |
Why?
|
Clinical Trials as Topic | 1 | 2009 | 195 | 0.080 |
Why?
|
Aspirin | 1 | 2007 | 45 | 0.080 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2008 | 129 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2009 | 203 | 0.070 |
Why?
|
Analysis of Variance | 2 | 2007 | 528 | 0.070 |
Why?
|
Arylamine N-Acetyltransferase | 1 | 2006 | 24 | 0.070 |
Why?
|
Androstenedione | 1 | 2006 | 16 | 0.070 |
Why?
|
Social Identification | 1 | 2007 | 49 | 0.070 |
Why?
|
Patient Education as Topic | 2 | 2011 | 207 | 0.070 |
Why?
|
Mental Recall | 2 | 2003 | 73 | 0.070 |
Why?
|
Androgens | 1 | 2006 | 87 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2005 | 187 | 0.070 |
Why?
|
Statistics, Nonparametric | 1 | 2006 | 106 | 0.070 |
Why?
|
Students | 2 | 2007 | 452 | 0.070 |
Why?
|
Europe | 3 | 2011 | 88 | 0.070 |
Why?
|
Evidence-Based Medicine | 1 | 2005 | 92 | 0.070 |
Why?
|
ROC Curve | 1 | 2005 | 138 | 0.070 |
Why?
|
Pregnanediol | 1 | 2005 | 5 | 0.070 |
Why?
|
Estriol | 1 | 2005 | 8 | 0.070 |
Why?
|
Poisson Distribution | 1 | 2005 | 39 | 0.070 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2005 | 75 | 0.060 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2005 | 52 | 0.060 |
Why?
|
Lymphoma | 1 | 2005 | 37 | 0.060 |
Why?
|
Gene Dosage | 1 | 2004 | 74 | 0.060 |
Why?
|
Research | 1 | 2006 | 159 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2005 | 82 | 0.060 |
Why?
|
Leukemia | 1 | 2005 | 54 | 0.060 |
Why?
|
Self Concept | 1 | 2005 | 136 | 0.060 |
Why?
|
Communication | 2 | 2003 | 170 | 0.060 |
Why?
|
Insurance Claim Reporting | 1 | 2003 | 4 | 0.060 |
Why?
|
Electric Impedance | 1 | 2023 | 23 | 0.060 |
Why?
|
Information Services | 1 | 2003 | 14 | 0.060 |
Why?
|
Spirituality | 1 | 2003 | 43 | 0.060 |
Why?
|
Dietary Fats | 3 | 2009 | 115 | 0.060 |
Why?
|
Menarche | 1 | 2022 | 13 | 0.060 |
Why?
|
Weight Loss | 1 | 2023 | 124 | 0.050 |
Why?
|
Health Systems Plans | 1 | 2002 | 1 | 0.050 |
Why?
|
Palpation | 1 | 2022 | 3 | 0.050 |
Why?
|
Mice | 1 | 2013 | 5668 | 0.050 |
Why?
|
Electronics | 1 | 2022 | 14 | 0.050 |
Why?
|
Patients | 1 | 2002 | 15 | 0.050 |
Why?
|
Growth | 1 | 2022 | 12 | 0.050 |
Why?
|
Estrogens, Non-Steroidal | 1 | 2002 | 17 | 0.050 |
Why?
|
Smoking Cessation | 2 | 2007 | 487 | 0.050 |
Why?
|
Sunlight | 2 | 2014 | 46 | 0.050 |
Why?
|
Luteinizing Hormone | 1 | 2002 | 62 | 0.050 |
Why?
|
Follicle Stimulating Hormone | 1 | 2002 | 41 | 0.050 |
Why?
|
Point-of-Care Systems | 1 | 2022 | 26 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2005 | 871 | 0.050 |
Why?
|
Disease Susceptibility | 2 | 2015 | 92 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2005 | 790 | 0.050 |
Why?
|
Metabolomics | 1 | 2021 | 76 | 0.050 |
Why?
|
Interpersonal Relations | 1 | 2003 | 198 | 0.050 |
Why?
|
Medicaid | 1 | 2002 | 102 | 0.050 |
Why?
|
Lipopolysaccharides | 1 | 2022 | 200 | 0.050 |
Why?
|
Adaptation, Psychological | 1 | 2003 | 358 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2004 | 531 | 0.040 |
Why?
|
Animals | 2 | 2013 | 14307 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 292 | 0.040 |
Why?
|
Pattern Recognition, Automated | 1 | 2018 | 30 | 0.040 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2016 | 16 | 0.040 |
Why?
|
Carcinoma, Endometrioid | 1 | 2016 | 17 | 0.040 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2016 | 40 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 435 | 0.040 |
Why?
|
International Agencies | 1 | 2015 | 5 | 0.040 |
Why?
|
Models, Biological | 1 | 2019 | 642 | 0.030 |
Why?
|
Water | 1 | 2018 | 283 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2016 | 102 | 0.030 |
Why?
|
Luciferases | 1 | 2015 | 62 | 0.030 |
Why?
|
Schools | 2 | 2007 | 229 | 0.030 |
Why?
|
Quantitative Trait Loci | 1 | 2015 | 68 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2015 | 159 | 0.030 |
Why?
|
Clostridium | 1 | 2014 | 19 | 0.030 |
Why?
|
Actinobacteria | 1 | 2014 | 9 | 0.030 |
Why?
|
Medical Record Linkage | 1 | 2014 | 15 | 0.030 |
Why?
|
Bacterial Typing Techniques | 1 | 2014 | 34 | 0.030 |
Why?
|
Carcinoma in Situ | 1 | 2014 | 13 | 0.030 |
Why?
|
Uric Acid | 1 | 2014 | 26 | 0.030 |
Why?
|
25-Hydroxyvitamin D 2 | 1 | 2014 | 9 | 0.030 |
Why?
|
Base Sequence | 1 | 2016 | 932 | 0.030 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2012 | 5 | 0.030 |
Why?
|
Protein Binding | 1 | 2016 | 913 | 0.030 |
Why?
|
Matrix Metalloproteinase 3 | 1 | 2012 | 14 | 0.030 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2012 | 22 | 0.030 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2012 | 47 | 0.030 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2012 | 58 | 0.030 |
Why?
|
Beer | 1 | 2011 | 4 | 0.030 |
Why?
|
Wine | 1 | 2011 | 9 | 0.030 |
Why?
|
Dietary Carbohydrates | 1 | 2011 | 30 | 0.030 |
Why?
|
Carbonated Beverages | 1 | 2011 | 21 | 0.020 |
Why?
|
Finland | 1 | 2010 | 10 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2010 | 27 | 0.020 |
Why?
|
Beverages | 1 | 2011 | 64 | 0.020 |
Why?
|
Seasons | 1 | 2010 | 112 | 0.020 |
Why?
|
Histamine Antagonists | 1 | 2009 | 6 | 0.020 |
Why?
|
Health Promotion | 2 | 2007 | 588 | 0.020 |
Why?
|
Alleles | 1 | 2010 | 284 | 0.020 |
Why?
|
Milk | 1 | 2009 | 48 | 0.020 |
Why?
|
Estrogen Receptor beta | 1 | 2009 | 37 | 0.020 |
Why?
|
Hyperparathyroidism | 1 | 2009 | 5 | 0.020 |
Why?
|
Factor Analysis, Statistical | 1 | 2009 | 125 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2009 | 298 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2009 | 122 | 0.020 |
Why?
|
Nicaragua | 1 | 2006 | 3 | 0.020 |
Why?
|
New Zealand | 1 | 2006 | 20 | 0.020 |
Why?
|
Africa | 1 | 2006 | 62 | 0.020 |
Why?
|
Cultural Characteristics | 1 | 2007 | 119 | 0.020 |
Why?
|
Australia | 1 | 2006 | 76 | 0.020 |
Why?
|
Family Characteristics | 1 | 2007 | 102 | 0.020 |
Why?
|
Peer Group | 1 | 2007 | 138 | 0.020 |
Why?
|
School Health Services | 1 | 2007 | 77 | 0.020 |
Why?
|
Social Behavior | 1 | 2007 | 124 | 0.020 |
Why?
|
Menstruation | 1 | 2005 | 10 | 0.020 |
Why?
|
Program Evaluation | 1 | 2007 | 316 | 0.020 |
Why?
|
Narration | 1 | 2005 | 27 | 0.020 |
Why?
|
Reference Values | 1 | 2005 | 204 | 0.020 |
Why?
|
Radiotherapy | 1 | 2005 | 15 | 0.020 |
Why?
|
Mastectomy | 1 | 2005 | 19 | 0.020 |
Why?
|
Adolescent Nutritional Physiological Phenomena | 1 | 2004 | 18 | 0.020 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 2004 | 37 | 0.020 |
Why?
|
Self Care | 1 | 2005 | 150 | 0.010 |
Why?
|
Faith Healing | 1 | 2003 | 4 | 0.010 |
Why?
|
Anecdotes as Topic | 1 | 2003 | 5 | 0.010 |
Why?
|
Pacific Islands | 1 | 2003 | 115 | 0.010 |
Why?
|
Professional Practice | 1 | 2002 | 3 | 0.010 |
Why?
|
Sampling Studies | 1 | 2002 | 60 | 0.010 |
Why?
|
Interview, Psychological | 1 | 2002 | 58 | 0.010 |
Why?
|
Personal Satisfaction | 1 | 2002 | 56 | 0.010 |
Why?
|
Culture | 1 | 2003 | 162 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2003 | 356 | 0.010 |
Why?
|
Motivation | 1 | 2004 | 415 | 0.010 |
Why?
|
Social Support | 1 | 2003 | 356 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2002 | 186 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2005 | 756 | 0.010 |
Why?
|